ArticleEuropean journal of nuclear medicine and molecular imaging2023
The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with
Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Dosimetry and pharmacokinetics of [European journal of nuclear medicine and molecular imaging · 2024Trial
- Patient Survival and Its Relation to Tumor Absorbed Dose in [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Dosimetry inJournal of clinical medicine · 2026Review
- Article
- Cumulative Absorbed Dose and Successive Cyclic Reduction in Absorbed Dose Predict Response toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Impact of partial volume correction on radiomics reproducibility in theranostic SPECT/CT imaging.Medical physics · 2026Article
- Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE.EJNMMI research · 2026Article
- Substantial decrease in tumor dose over subsequent cyles of [European journal of nuclear medicine and molecular imaging · 2025Article
- Blood-based transcriptomic biomarkers for response to [EJNMMI research · 2025Article
- Safety and efficacy of re-treatment with [European journal of nuclear medicine and molecular imaging · 2025Article
- Multicycle Dosimetric Behavior and Dose-Effect Relationships in [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Quantitative 177Lu-DOTATATE SPECT/CT is predictive of 6-month PRRT morphological response in midgut neuroendocrine tumors: a pilot study.EJNMMI research · 2025Article
- Robustness of textural analysis features in quantitativeEJNMMI physics · 2025Article
- Dosimetry Software for Theranostic Applications: Current Capabilities and Future Prospects.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Review
- EANM expert opinion: How can lessons from radiobiology be applied to the design of clinical trials? Part I: back to the basics of absorbed dose-response and threshold absorbed doses.European journal of nuclear medicine and molecular imaging · 2025Review
- Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.EJNMMI research · 2024Article
- Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence.European journal of nuclear medicine and molecular imaging · 2024Article
- The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Prediction of [EJNMMI physics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide Receptor Radionuclide Therapy (PRRT) delivers targeted radiation to Somatostatin Receptor (SSR) expressing Neuroendocrine Neoplasms (NEN). We sought to assess the predictive and prognostic implications of tumour dosimetry with respect to response by
methodsPatients with gastro-entero-pancreatic (GEP) NEN who received LuTate followed by quantitative SPECT/CT (Q-SPECT/CT) the next day (Jul 2010 to Jan 2019) were retrospectively reviewed. Single time-point (STP) lesional dosimetry was performed for each cycle using population-based pharmacokinetic modelling. MITV
resultsMedian of 4 PRRT cycles were administered to 90 patients (range 2-5 cycles; mean 27.4 GBq cumulative activity; mean 7.6 GBq per cycle). 68% received at least one cycle with radiosensitising chemotherapy (RSC). RECIST 1.1 partial response was 24%, with 70% stable and 7% progressive disease. Cycle 1 radiation dose in measurable lesions was associated with local response (odds ratio 1.5 per 50 Gy [95% CI: 1.1-2.0], p = 0.002) when adjusted by tumour grade and RSC. Median change in MITV
conclusionRadiation dose to tumour during PRRT was predictive of radiologic response but not survival. Survival outcomes may relate to other biological factors. There was no evidence that MITV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.